Operating Segments

3 Months Ended

Mar. 31, 2015

Operating Segments [Abstract]

Operating Segments

Note 8. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended March 31,
	2015			2014
Contract/Grant Revenue
Vaccines/BioDefense	$	802,314		$	877,045
BioTherapeutics		13,972			33,552
Total	$	816,286		$	910,597
Income/(Loss) from Operations
Vaccines/BioDefense	$	84,681		$	139,404
BioTherapeutics		(764,876	)		(1,035,591	)
Corporate		(878,072	)		(693,722	)
Total	$	(1,558,267	)	$	(1,589,909	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,786		$	9,935
BioTherapeutics		48,374			49,939
Corporate		1,766			2,213
Total	$	59,926		$	62,087
Interest Income
Corporate	$	561		$	291
Share-Based Compensation
Vaccines/BioDefense	$	24,592		$	10,450
BioTherapeutics		29,256			76,121
Corporate		88,177			90,091
Total	$	142,025		$	176,662

	As of March 31, 2015		As of  December 31,  2014
Identifiable Assets
Vaccines/BioDefense	$	568,565	$	1,025,220
BioTherapeutics		161,355		204,308
Corporate		5,172,737		5,724,720
Total	$	5,902,657	$	6,954,248